title: Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma.
abstract: BACKGROUND
  Recent studies proposed neutrophil-to-lymphocyte ratio (NLR) as a prognostic biomarker in malignant pleural mesothelioma (MPM). We examined baseline prognostic variables including NLR and the EORTC and CALGB models as predictors of overall survival (OS) in MPM.
  
  
  METHODS
  In this retrospective study, 274 consecutive eligible, newly presenting patients with MPM were included. Of these, 159 received chemotherapy, 10 had tri-modality therapy, 2 underwent surgery only and 103 received supportive care alone. Univariate analyses and multivariate Cox models were calculated for OS.
  
  
  RESULTS
  In univariate analysis, poor prognostic factors were: age ≥65 years, nonepithelioid histology, stage III-IV, poor performance status (PS), weight loss, chest pain, low haemoglobin and high platelet count. A baseline NLR≥ 5 did not predict worse OS (hazard ratio (HR) 1.25; P=0.122). On multivariate analysis, age, histology, PS, weight loss, chest pain and platelet count remained significant. The EORTC and CALGB prognostic groups were validated as predictive for OS (HR 1.62; P<0.001 and HR 1.65; P<0.001, respectively).
  
  
  CONCLUSIONS
  Our findings validate standard prognostic variables and the existing EORTC and CALGB models, but not NLR, at initial diagnosis of MPM. In guiding patient management at diagnosis, it is important to consider multiple baseline variables that jointly predict survival.
authors: 1] M503, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia [2] National Centre for Asbestos Related Disease, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia [3] Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia.
authors: T M
authors: TM
authors: Meniawy
authors: J
authors: J
authors: Creaney
authors: R A
authors: RA
authors: Lake
authors: A K
authors: AK
authors: Nowak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality*; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000166:cytology*; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy / Q000401:mortality*; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor
references: J Clin Oncol. 2003 Jul 15;21(14):2636-44
references: 12860938
references: N Engl J Med. 2012 Oct 4;367(14):1355-60
references: 23034025
references: J Clin Oncol. 1998 Jan;16(1):145-52
references: 9440736
references: Clin Lung Cancer. 2013 Jan;14(1):70-7
references: 22658812
references: Ann Oncol. 2004 Feb;15(2):257-60
references: 14760119
references: Cancer Immunol Immunother. 2011 Dec;60(12):1721-8
references: 21769693
references: Clin Cancer Res. 2010 Dec 1;16(23):5805-13
references: 20956618
references: J Thorac Oncol. 2011 Nov;6(11):1923-9
references: 22011651
references: J Clin Oncol. 2005 Jan 1;23(1):184-9
references: 15625372
references: Thorax. 2000 Sep;55(9):731-5
references: 10950889
references: J Clin Oncol. 2012 Sep 10;30(26):3297-303
references: 22649133
references: Chest. 1998 Mar;113(3):723-31
references: 9515850
references: J Clin Oncol. 2005 Dec 20;23(36):9067-72
references: 16172462
references: Lung Cancer. 2012 Jul;77(1):192-8
references: 22459204
references: Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
references: 19318937
references: Br J Cancer. 2004 Jul 5;91(1):4-8
references: 15188004
references: J Nucl Med. 2007 Sep;48(9):1449-58
references: 17704250
references: J Thorac Oncol. 2012 Mar;7(3):587-94
references: 22307011